InvestorsHub Logo
Followers 47
Posts 12038
Boards Moderated 0
Alias Born 09/12/2017

Re: justdafactss post# 229405

Friday, 02/02/2024 3:41:46 PM

Friday, February 02, 2024 3:41:46 PM

Post# of 232959
FDA said--- With the conclusion of both the CD10 and CD12 clinical trials, it has become clear that the data currently available do not support the clinical benefit of leronlimab for the treatment of COVID-19. In the smaller study that CytoDyn conducted in patients with mild-to-moderate COVID-19 disease (CD10), there was no observed effect of the drug on the study’s primary endpoint or on any of the secondary endpoints.
https://www.fda.gov/drugs/drug-safety-and-availability/statement-leronlimab

Hmmm....Proactive video says 'Strong results', FDA says "there was no observed effect of the drug on the study’s primary endpoint or on any of the secondary endpoints."

Whos telling the truth and who aint?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News